Shield Therapeutics Share Discussion Threads

[minky] 03/5/2018 08:40

IG Closing only will not allow BUY

[holiday6] 02/5/2018 18:23

Looks like major institutional seller has been cleared out - trades at 15.5 and 16 mostly yesterday and so the continual downward pressure has been relieved. If they have enough cash then shares are very cheap. If they get the FDA approval then very very cheap!

[ohsod1t] 02/5/2018 17:50

Was REDX on the list? They have hired the president of AstraZeneca as chief executive recently.Any others of note?

[ny boy] 02/5/2018 17:33

Peel Hunt identity Shield and a few others as possible bid targets, there is a feed on Twitter about it.

Bodes well for some upside here imho

[sux_2bu] 02/5/2018 17:02

looks interesting

[ohsod1t] 02/5/2018 16:50

Me too.....looks like they are on the up. Finished on the high of the day without real news. Maybe something leaked to friends and family.

[ny boy] 02/5/2018 16:34

Yep I bought in today, one to hold and await further developments

[rakepat37] 02/5/2018 09:29

Looks like twitter feeds are mentioning a potential take over target... wow, seriously under valued stock

[rakepat37] 02/5/2018 09:07

We should be sitting at 35p minimum with a up swing once news break with updates to 50p+

[rakepat37] 01/5/2018 16:01

Seriously undervalued stock and really hard to buy at the mo, took 10 mins to buy via phone. This will rise fast

[toadhall1] 13/4/2018 09:04

Been watching this for a while. Although positive news on expanded licence, the question for me also is what is going to trigger clinicians to prescribe the drug for general anaemia, given trials have only been with anaemia with CKD (failed) and IBD. And from what I gather it's more expensive. Surely they need to present evidence of how much better it would be for general anaemia otherwise why would the medical community take it up? Otherwise for now I'll wait to see what mngt say in the strategic review.

[bobf1] 12/4/2018 22:49

Yes, the expanding licence is interesting; although the CEO states that the lack of promotional activity to enhance sales is going to inhibit this. Early days, but the slashing of the headcount may take time to get the former up-and-running again. Quite an alarming net loss, but patient uptake may kick in. Depends on the NHS price of the drug, as clinicians tend to favour equivalent, but less-expensive medication.

[optrade] 12/4/2018 07:04

hxxps://www.chroniclelive.co.uk/business/business-news/gateshead-pharmaceutical-firm-reveals-big-14518892
Gateshead pharmaceutical firm reveals big price of failed US drug study
Shield Therapeutics has been through a 'transformational' year pushing its iron deficiency drug Ferracru
15:35, 11 APR 2018
Full-year results from Gateshead pharm a firm Shield Therapeutics lay bare the high price of a drug study which has delayed its attempts to get into the lucrative US market, and resulted in “significant” job losses.

The company announced in February it was significantly reducing its headcount to save cash after a study appeared to show its iron deficiency drug Ferracru had failed to reach trial targets needed to get into the US – wiping more than 85% off its market value.

However, further analysis of the results of the study, which involved 168 patients, show they had been skewed by number of patient-specific events that the company believe adversely impacted the study.

Now, following feedback from the American Food and Drug Administration (FDA), the firm is gearing up to submit a second application in the US to approve its main product.

The high price of that first AEGIS-CKD study is laid bare in full year results posted by the AIM-listed company, however.

Ferracru, Shield Therapeutics' main product
Ferracru, Shield Therapeutics' main product (Image: Shield Therapeutics)
The results, for the year ended December 31 2017, show plans to ramp up commercialisation of Ferracru in the UK and Europe were on track, with a strategy to take on 20 extra sales staff also on track.

During the period, revenues doubled from £304,000 to £637,000 – the majority of which came from Europe – and Feraccru was out licensed across additional markets in Scandinavia and Switzerland. The firm has also now enlisted a third party to explore further options to grow in Europe.

Shield’s net loss widened from £15m to £19.6m, primarily in relation to ongoing commercialisation and research and development activities, and selling costs also grew from £4.2m to £9.1m as commercial activities were developed in Europe.

The results also show the AEGIS-CKD study and additional costs associated with the Marketing Authorisation Approval cost the business £4.7m.

Chairman Andrew Heath paid tribute to staff who had been affected by the firm’s decision to slash the headcount.

He said: “2017 was another year of solid progress for Shield, the results of which, however, have been significantly affected by post period events.

“The board and I would like to thank all of Shield’s employees and its partners who have continued to show tremendous commitment and worked hard to deliver our corporate objectives and goals through a transformational period for the group. The decisions the board and management had to take immediately after receipt of the initial top-line results of the Phase III AEGIS-CKD study to reduce the operational activity and headcount of the business were particularly difficult, but completely necessary to protect our financial resources.

“The board and I offer our sincere gratitude to all those who have been affected and who have shown continued commitment in difficult times.”

CEO Carl Sterritt said the firm has been making progress in Germany and the UK and emphasised how Ferracru has big potential.

He said: “Product awareness is growing, and more patients than ever are benefitting from Feraccru. During the first months of 2018 we have continued to see positive month-on-month growth in demand for Feraccru in both Germany and the UK.

“With the approval of a broad label to treat iron deficiency, the potential for Feraccru to become a mainstay of therapy for patients with this debilitating condition is very real.

“As a result of the company taking positive actions to preserve cash following the initial study top-line results reporting, the board believes that the company has sufficient cash resources to fund the business until at least the end of Q4 2018.


“However, as this is being primarily achieved through a significant reduction in Shield’s own headcount and promotional activities related to Feraccru, with further cost containment remaining an ongoing priority, this is likely to impact sales of Feraccru.

“However, we are evaluating ways of maintaining Feraccru’s share of voice in the marketplace to continue to build on the solid progress made to date.”

[vitaline101] 02/3/2018 09:04

They have made 2/3 employees redundant in the U.K., the product is 2 years’ old and has hardly gained any significant use in hospitals or primary care - despite what their report says. At £50 a month it is more expensive than intravenous therapy which is a tried and tested method of treating anaemia.
Moreover, the data shows Feraccru has an efficacy less than - or equivalent to a placebo. It may have a CHMP rating but there is no data to display its efficacy, and they have no sales force in the U.K. promoting or selling it. They have cut staff to use the money to invest in a clinical trial to try and show that Feraccru is vaguely effective. In the key renal trial they recently published the results were disastrous.

[dave4545] 01/3/2018 11:27

Signs of life 400k of volume

Still offering at mid price 18p now.

Took 10k as a starter

[dave4545] 01/3/2018 10:38

No signs of a bounce yet.

Can buy unlimited amounts at 17.5p mid price.

Will keep watching

[mickluv1] 28/2/2018 10:20

I've been tracking this for a few weeks now! Where do people think the bottom is? is this a duster?

[pugugly] 05/2/2018 10:17

Top list faller Some 50% down rns states basic failure but no comments here - Has everyone who was holding sold up and left ??

[vitaline101] 04/12/2017 17:40

These prices are falling ridiculously; by about 30% in the last month. Nearly all of the recent trades are 'sell'. The product doesn't seem to have taken off in the UK at all

[el chupacabra] 17/2/2015 18:36

Bloomberg’s Cory Johnson reports on Kaspersky Lab finding concealed software on drives made by Western Digital, Seagate, Toshiba and others. Johnson speaks on “Market Makers.”

[bracke] 20/1/2015 17:31

Thanks Babywolf.

[babywolf] 20/1/2015 17:28

Gosh Bracke - am sorry.
I remember reading a post of yours on the FX and wanted to drop you a line.
I forgot and you've just jogged my memory.
I hope you are your nearest and dearest are ok?

[babywolf] 20/1/2015 15:29

Hi Penycae

'irritating a few people on the BP thread' - surely not!
It has to be better than those who post on the FX thread - it's often pistols at dawn but not phrased nearly as politely.

I know exactly what you're saying about oil.
One comment could have it rocket up and I DO trade oil as if each trade might be the last one at the low price.

One day, you'll have to explain what looking after the family jools entails :)

Now all we need is for Bracke to check in...